Concepedia
Statistics
Publications
9
Citations
775
H-Index
Active since
2004
Affiliations
AstraZeneca (United Kingdom)(Current)
University of Manchester
Cancer Research UK Manchester Institute
Cancer Research UK
Sarah V. Holt is an author at AstraZeneca (United Kingdom) specializing in medicine, cell biology, and tumor biology.
Top concepts
MedicineCell BiologyTumor BiologyPharmacologyNatural SciencesGeneticsOncologyChromatinCell CycleCell Death
Publications per year
2004–2020
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
Victoria Johnson, Maria I. F. Scott, Sarah V. Holt et al. · Journal of Cell Science · 2004 · 342 citations
Cytogenetics, Genetics, Molecular Genetics +16
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
Sarah V. Holt, Armelle Logié, Rajesh Odedra et al. · British Journal of Cancer · 2012 · 111 citations · Full text
Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint
Sarah V. Holt, M. Vergnolle, Deema Hussein et al. · Journal of Cell Science · 2005 · 107 citations
Genetics, Molecular Genetics, Cytoskeleton +17
Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)
Sarah V. Holt, Armelle Logié, Barry R. Davies et al. · Cancer Research · 2012 · 83 citations
Dual Mtorc1, Mtor Kinase Inhibitors, Medicine +12
The Development of an Immunohistochemical Method to Detect the Autophagy-Associated Protein LC3-II in Human Tumor Xenografts
Sarah V. Holt, Beata S. Wyspiańska, Kevin J. Randall et al. · Toxicologic Pathology · 2011 · 52 citations
Mitophagy, Immunology, Cell Death +18
1–5 of 9